New hope for advanced prostate cancer: experimental drug enters human trials

NCT ID NCT05800665

Recruiting now Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This early-stage trial is testing an experimental oral drug called RO7656594 in people with advanced or metastatic prostate cancer that has progressed after standard treatments. The study aims to find safe doses and check for any signs that the drug can shrink tumors or lower PSA levels. About 210 participants will receive the drug at different doses to see how well it is tolerated and how the body processes it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RO7656594 (also called GDC-2992), an oral drug
What this could lead to: If successful, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to other therapies.
What could go wrong: This is an early Phase 1 trial with only 210 participants, focused on safety and dosing. It is too soon to know if the drug will work or have manageable side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PROSTATE CANCER METASTATIC PROSTATE CANCER

Contacts and locations

Locations

Asan Medical Center - PPDS
RECRUITING

Seoul, 05505, South Korea
Austin Hospital
RECRUITING

Heidelberg, Victoria, 3084, Australia
British Columbia Cancer Agency
RECRUITING

Vancouver, British Columbia, V5Z 4E6, Canada
Cambridge Clinical Research Centre
RECRUITING

Cambridge, CB2 0AU, United Kingdom
Centre Léon Bérard
RECRUITING

Lyon, 69008, France
Clinica Universidad de Navarra
RECRUITING

Pamplona, Navarre, 31008, Spain
Clinica Universidad de Navarra-Madrid
RECRUITING

Madrid, 28027, Spain
Gustave Roussy
RECRUITING

Villejuif, Val-de-Marne, 94805, France
HonorHealth
RECRUITING

Scottsdale, Arizona, 85258, United States
Hospital Clinico San Carlos
RECRUITING

Madrid, 28040, Spain
Hospital Universitario Vall d'Hebron - PPDS
RECRUITING

Barcelona, 08035, Spain
Institut Paoli Calmettes
RECRUITING

Marseille, 13009, France
Leicester Royal Infirmary
RECRUITING

Leicester, LE1 5WW, United Kingdom
Macquarie University Hospital
RECRUITING

New South Wales, New South Wales, 2162, Australia
Monash Health Monash Medical Centre
RECRUITING

Clayton, Victoria, 3168, Australia
Princess Margaret Hospital
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Royal Marsden Hospital - Surrey
RECRUITING

Sutton, SM2 5PT, United Kingdom
SCRI Oncology Partners
RECRUITING

Nashville, Texas, 37203, United States
Samsung Medical Center - PPDS
RECRUITING

Seoul, 06351, South Korea
Sarah Cannon Research Institute @ Florida Cancer
RECRUITING

Orlando, Florida, 32827, United States
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Severance Hospital Yonsei University Health System - PPDS
RECRUITING

Seoul, 03722, South Korea
St Vincent's Hospital Sydney
RECRUITING

Darlinghurst, New South Wales, 2010, Australia
The Christie
RECRUITING

Manchester, M20 4BX, United Kingdom
University of Illinois Hospital & Health Sciences System
RECRUITING

Chicago, Illinois, 60612, United States
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.